A Clinical Study of IL13Rα2 Targeted CAR-T in Patients With Malignant Glioma (MAGIC-I)
Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
This is a phase I study to evaluate the safety and tolerability of IL13Rα2 Targeted Chimeric
Antigen Receptor-T Cell in patients with Refractory or Recurrent Malignant Glioma and to
evaluate the changes of AE incidence.